Learn more: PMC Disclaimer | PMC Copyright Notice
Ptpn11 Deletion in A Novel Cartilage Cell Causes Metachondromatosis by Activating Hedgehog Signaling
Associated Data
Abstract
SHP2, encoded by PTPN11, is required for survival, proliferation and differentiation of various cell types1,2. Germ line activating mutations in PTPN11 cause Noonan Syndrome, while somatic PTPN11 mutations cause childhood myeloproliferative disease and contribute to some solid tumors. Recently, heterozygous inactivating mutations in PTPN11 were found in metachondromatosis, a rare inherited disorder featuring multiple exostoses, endochondromas, joint destruction and bony deformities3,4. The detailed pathogenesis of this disorder has remained unclear. Here, we used a conditional knockout allele (Ptpn11fl) and Cre recombinase (Cre) transgenic mice to delete Ptpn11 specifically in monocytes, macrophages and osteoclasts (lysozyme M-Cre; LysMCre) or in cathepsin K (Ctsk)-expressing cells, previously thought to be osteoclasts. LysMCre;Ptpn11fl/fl mice had mild osteopetrosis. Surprisingly, however, CtskCre;Ptpn11fl/fl mice developed features strikingly similar to metachondromatosis. Lineage tracing revealed a novel population of Ctsk-Cre-expressing cells in the “Perichondrial Groove of Ranvier” that display markers and functional properties consistent with mesenchymal progenitors. Chondroid neoplasms arose from these cells and showed decreased Erk activation, increased Indian Hedgehog (Ihh) and Parathyroid hormone-related protein (Pthrp) expression and excessive proliferation. Shp2-deficient chondroprogenitors had decreased FGF-evoked Erk activation and enhanced Ihh and Pthrp expression, whereas FGFR or MEK inhibitor treatment of chondroid cells increased Ihh and Pthrp expression. Most importantly, Smoothened inhibitor treatment ameliorated metachondromatosis features in CtskCre;Ptpn11fl/fl mice. Thus, in contrast to its pro-oncogenic role in hematopoietic and epithelial cells, Ptpn11 is a tumor suppressor in cartilage, acting via an FGFR/MEK/ERK-dependent pathway in a novel progenitor cell population to prevent excessive Ihh production.
Cartilage tumors, including exostoses, enchondromas and chondrosarcomas, comprise ~20% of skeletal neoplasms5. Benign and malignant cartilaginous tumors can arise sporadically, but cartilage tumor syndromes, including hereditary multiple exostoses (HME), the multiple enchondromatosis disorders (Ollier disease and Maffucci syndrome), and metachondromatosis (MC), also exist6,7. The cellular and molecular pathogenesis of most cartilage tumors is incompletely understood.
MC is an autosomal dominant tumor syndrome featuring multiple exostoses and enchondromas6,7. Recently, heterozygous early frameshift or nonsense mutations in PTPN11 were identified in >50% of MC cases3,4. PTPN11 encodes the non-receptor protein-tyrosine phosphatase SHP2, which is required for RAS/ERK pathway activation in most receptor tyrosine kinase, cytokine receptor, and integrin signaling pathways1,2. Germ line activating mutations in PTPN11 cause Noonan syndrome (NS), whereas mutations that impair SHP2 catalytic activity cause LEOPARD syndrome (LS), both of which can feature skeletal abnormalities8. Somatic activating mutations in PTPN11 are the most common cause of juvenile myelomyelogenous leukemia (JMML) and contribute to other leukemias and some solid tumors1,2. Although PTPN11 is a well-established human oncogene, it is unclear how heterozygous loss-of-function PTPN11 alleles cause cartilage neoplasms.
Global Ptpn11 deletion results in early embryonic lethality9,10, whereas postnatal deletion has context-dependent effects1,2. To assess the role of Shp2 in osteoclasts (OC), we crossed Ptpn11fl mice10 to mice expressing Cre under the control of the endogenous lysozyme M (LysM)11 or cathepsin K12 (Ctsk) promoter. The LysM promoter is active in monocytes, macrophages and osteoclast precursors11, whereas the Ctsk promoter reportedly is active only in mature OC12,13. These crosses generated Ptpn11fl/+;LysMCre and Ptpn11fl/fl;LysMCre (hereafter, LysM-Control and LysM-KO) and Ptpn11fl/+;CtskCre and Ptpn11fl/fl;CtskCre (hereafter, Ctsk-Control and Ctsk-KO) mice, respectively (Fig. 1a).
Ptpn11 deletion in Cathepsin K-expressing cells causes metachondromatosis. a, Schemes for generating Ctsk-KO, LysM-KO, and Control mice. Gross images (b) and Faxitron/μ-CT radiographs (c) of 12 week-old Ctsk-KO mice showing dwarfism and scoliosis (b.ii, white arrow; c.ii, black arrow), increased bone mineral density (c.ii,iv) and multiple exostoses of knees, ankles, and metatarsals (b.iv; c.ii,iv,vi,viii; arrowheads) with joint destruction. d, Sagittal sections of metatarsal joints stained with H&E (i–iii), Safranin O (iv–vi) and Alcian blue (vii–ix) showing cartilaginous exostoses and enchondromas (arrows) in Ctsk-KO mice. Images in iii, vi and ix are magnified (10X) views of boxed areas in ii, iv and viii, respectively. Data shown are representative images; each analysis was performed on at least 5 mice/genotype.
Neither Ptpn11fl/+;LysMCre, nor Ptpn11fl/+;CtskCre, mice had a discernible phenotype, so we focused all subsequent analyses on LysM-KO and Ctsk-KO mice. Shp2 levels were reduced by >80% in bone marrow-derived macrophages (BMM) and OC in LysM-KO and Ctsk-KO mice (Fig. S1a and data not shown). LysM-KO and Ctsk-KO mice were born at the expected Mendelian ratios and appeared normal for their first 3 weeks post-birth. Subsequently, LysM-KO mice developed mild, age-related osteopetrosis (Fig. S1b and data not shown). By contrast, within eight weeks after birth, Ctsk-KO mice exhibited a dramatic skeletal phenotype, comprising decreased body length, increased bone mineral density, scoliosis, metaphyseal exostoses and markedly decreased mobility (Fig. 1b–d & Supplementary video clips 1,2). Sections of hind limb paw and knee joints from 12-week-old Ctsk-KO mice revealed multiple exostoses and enchondromas at the metaphyses of their metatarsals and phalanges (Fig. 1d), tibiae and femurs (Fig. S1c,d), and other bones (data not shown), features reminiscent of MC. As heterozygous PTPN11 frameshift mutations cause MC3,4, these findings indicate that PTPN11 is a cartilage tumor suppressor gene, and suggest that loss (or silencing) of the remaining PTPN11 allele is required for tumor formation.
To identify the cells responsible for MC-like disease in Ctsk-KO mice, we first injected bone marrow (BM) from 6-week-old Ctsk-KO and Ctsk-Control mice (C57/BL6; CD45.2) into lethally irradiated 3-week-old recipients (B6.SJL; CD45.1). Recipient mice exhibited high chimerism (Fig. S2a,b), but did not develop cartilage tumors in over 12 months of observation. Consistent with the osteopetrosis seen in LysM-KO mice, recipients had increased bone mineral density (Fig. S2c). Clearly, though, cartilage tumors in Ctsk-KO mice are not due to altered OC development/function.
Next, we performed lineage-tracing studies, using Rosa26LSL-lacZ (R26LSL-lacZ) or Rosa26LSL-YFP (R26LSL-YFP) Cre reporter mice. Remarkably, CtskCre, but not LysMCre, was expressed in a subset of perichondrial cells within the so-called “Groove of Ranvier” (Fig. 2a). Sections from knee joints collected at P10 revealed significant expansion of a cluster of Alcian blue/Safranin O-positive cells in this region in Ctsk-KO, mice, but not in Controls (Fig. 2b, boxed region and Fig. S1c). By post-natal week 2, the YFP+ cell population had expanded and differentiated into ectopic cartilaginous tissue in compound Ctsk-KO/YFP reporter mice (Fig. 2c, boxed region). Exostoses were palpable at 6 weeks and visible by 8–12 weeks. In compound Ctsk-KO/YFP reporter mice, these lesions consisted of YFP+ chondroid cells at various stages of development, including proliferating, pre-hypertrophic, and hypertrophic chondrocytes, as revealed by cell morphology and Col2α1 and Col10α1 immunostaining (Fig. 2c,d and data not shown). Notably, nearly all chondroid tumor cells were YFP+ (Fig. 2c and S2d). Hence, cartilaginous tumors in Ctsk-KO mice (and, by analogy, most likely in MC) result from cell-autonomous lack of Shp2 in Ctsk+ cells from the Perichondrial Groove of Ranvier.
Skeletal tumors in Ctsk-KO mice originate from Perichondrial Groove of Ranvier cells. a, X-gal staining of knee joint sections from 1-week-old R26LSLlacZ;Ctsk-Cre and R26LSLlacZ;LysM-Cre reporter mice showing that the Ctsk (but not the LysM) promoter is active not only in osteoclasts, but also in a subset of cells from the Perichondrial Groove of Ranvier (arrows). b, H&E and Safranin O staining of knee joint sections from P10 Ctsk-Control (i,iv) and Ctsk-KO (ii,iii,v,vi) mice showing expansion of cells within the Perichondrial Groove of Ranvier region in Ctsk-KO mice. Images in iii & vi are magnified (10x) views of boxed areas in ii & v respectively; c, H&E-and Safranin O-stained sections showing expanding YFP+ population within the Perichondrial Groove of Ranvier (boxed region in top panels, magnified below) that also stains with Safranin O, indicative of cartilage. Dashed line marks boundary between marrow/growth plate and perichondrial groove. d, frozen section of an exostosis from the metatarsal joint of Ctsk-KO/YFP mice showing co-localization of YFP reporter with cartilaginous tumor cells (boxed area). Note that the lesion is enriched in proliferating and pre-hypertrophic chondrocytes, as shown by overlapping Col2α1 and Col10α1 immunostaining. Each panel is a representative image from one mouse; each analysis was performed on at least 3 mice/genotype.
The Perichondrial Groove of Ranvier is believed to contain chondroprogenitors responsible for circumferential cartilage growth, but these cells are not well-characterized14,15. We used flow cytometry to analyze epiphyseal cartilage cells harvested from the distal femurs and proximal tibiae of Ctsk-Control/YFP and Ctsk-KO/YFP mice at P10–12. Compared with controls, the frequency of YFP+ cartilage cells in Ctsk-KO/YFP mice was increased by ~5-fold (Fig. 3a). Within the YFP+ cell population, the percentage of cells expressing CD44, CD90, and CD166 (mesenchymal progenitor markers), but not CD31 (endothelial cell marker), also was increased (Fig. 3b). Staining for Stro1 and Jagged1, markers associated with presumptive chondroprogenitors in the groove based on BrdU label retention studies16, was more intense in Ctsk-KO mice (Fig. 3c). Moreover, YFP+ cells were capable of multi-lineage differentiation in vitro, as assessed by Alcian Blue, Oil Red O and Alizarin red staining, respectively (Fig. 3d). These data suggest that Shp2 regulates the proliferation of a novel cartilage cell population characterized by Ctsk expression, which we hereafter term “Ctsk+ Chondroid Progenitors” (CCPs).
Ptpn11 deletion in Ctsk-expressing cells causes expansion of novel chondroprogenitor cell population within the Perichondrial Groove of Ranvier. a, Flow cytometric analysis showing YFP+ cells from pooled epiphyseal cartilage from 5–7 Ctsk-Control/YFP mice; note increased percentage of such cells in 2-week-old Ctsk-KO/YFP mice. CC: Chondroid cells. b, Flow cytometric analysis of YFP+ perichondrial cells showing staining for CD31, CD44, CD90, and CD166. Data in panels a and b are from a single experiment; similar results were obtained in 2 additional experiments. c, Immunofluorescence micrograph showing Stro1 and Jagged1 expression in YFP+ perichondrial cells. Nuclei are stained with DAPI. Note enhanced intensity of Stro1 and Jagged staining in Ctsk-KO cells. Data shown are from single mice of each genotype; two additional mice were analyzed for each genotype with similar results. d, CCPs give rise to cartilage, fat and bone. FACS-purified YFP+ cells from 5–7 mice were subjected to differentiation assays in triplicate. After 2–3 weeks of culture (see Methods), cells were fixed and stained with Alcian blue, Oil red, and Alizarin red to visualize the formation of cartilage, fat, and bone tissue, respectively.
Multiple pathways control cartilage development and homeostasis17. Indian hedgehog (IHH) and Parathyroid hormone-related protein (PTHRP) signaling are particularly important, and aberrant regulation of these pathways causes developmental defects and skeletal tumors18,19. We examined chondrogenic gene expression in cartilage tumors from Ctsk-KO mice by quantitative reverse-transcription PCR (qRT-PCR). Consistent with our immunostaining data (Fig. 2d), Col2α1 and Col10α1 transcripts were increased. Furthermore, Ihh and Pthrp levels were elevated substantially (Fig. 4a, S3a).
Shp2 deficiency impairs Erk activation but promotes Ihh and Pthrp expression. a, (Left panel) qRT-PCR showing increased Col2α1, Col10α1, Ihh, and Pthrp expression in laser-captured cartilaginous cells from exostoses in 4 mice/genotype, compared with normal articular cartilage cells (mean±S.D; *p<0.05, 2-tailed Student’s t test). (Right panel) Immunostaining of representative paraffin sections from Perichondrial Groove of Ranvier region of Ctsk-KO and Control mice. Note the decreased number of p-Erk+ cells (75.4% in Ctsk-Control vs 32.2% in Ctsk-KO; n=3 mice), but increased Ihh expression in Ctsk-KO, compared with Control, mice. b, (Left Panel) Immunoblot showing Shp2 in ATDC5 cells stably expressing shRNAs against mouse Ptpn11 (ATDC5-KD1, ATDC5-KD2, respectively) or scrambled control hairpin. (Right panels). Representative blot showing that Shp2 deficiency decreases Erk activation in response to Fgf18 (top); data from multiple experiments (n=3) showing pErk levels (compared with control at 5 minutes, mean±S.D.; p<0.05, 2-tailed Student’s t test) are quantified below. qRT-PCR (bottom left) shows increased Ihh and Pthrp expression in Shp2-deficient ATDC5 cells (mean ± S.D.; n=3, *p<0.05, 2-tailed Student’s t test). c, FGFR (PD173074, 10nM) or MEK (UO126, 1μM) inhibitor treatment of parental ATDC5 cells enhances Ihh and Pthrp expression, as shown by qRT-PCR (mean±S.D; n=3, *p<0.05, 2-tailed Student’s t test). d, Faxitron radiographs showing that Hedgehog pathway blockade following administration of the Smoothened inhibitor PF-04449913 (100μg/g body weight) to Ctsk-KO mice ameliorates tumor formation, compared with vehicle control (0.5% methylcellulose)-treated mice. Images of representative posterior paws (i–iv) and knees (v–vii) taken pre- (i,iii,v,vii) and post-treatment with Vehicle (ii,vi) or Smoothened inhibitor (SMOi) (iv,viii) for 4 weeks. Note continued development of exostoses and endochromas in Vehicle-treated mice, and their amelioration in SMOi-treated group (arrows). Also, see Figs. S4–S7 and Supplemental video clips 1,2.
These findings prompted us to ask whether Shp2 regulates Ihh and Pthrp production, and if so, how. During development, cells within the perichondrium make Fgf18, which can signal to adjacent cells via Fgfr3 to suppress Ihh expression20,21. As Shp2 is required for Fgfr signaling in other cell types1,2, we suspected that Shp2 might be required for Fgfr3-induced suppression of Ihh expression. We therefore examined the status of Fgfr3 signaling components and Ihh expression in CCPs. Erk activation, as assayed by Tyr204Thr202 phosphorylation, was compromised in the absence of Shp2, whereas Akt (p-Ser473) and Stat1/3 (p-Tyr807) activation were unaffected (Fig. 4a, S3b & data not shown). Furthermore, consistent with our qRT-PCR data, Ihh mRNA and protein were elevated in Shp2-deficient CCPs (Fig. 4a). Ihh antibody specificity was confirmed by immunostaining of growth plate cartilage (Fig. S3c).
CCPs are rare, rendering their detailed biochemical analysis unfeasible. We therefore tested the effects of Shp2 depletion in ATDC5 chondroid cells by stably expressing either of two shRNAs targeting mouse Ptpn11. As in Ctsk-KO mice (Fig. 4a), Fgf18-evoked Erk activation was decreased, while Ihh and Pthrp levels were increased in Shp2-deficient cells (Fig. 4b). Conversely, FGFR (PD173074) or MEK (UO126) inhibition led to enhanced Ihh and Pthrp expression in parental ATDC5 cells (Fig. 4c).
Ihh signaling evokes Pthrp production22. Our data, and previous studies23, suggested that increased Ihh levels might be pathogenic in MC. If so, then blocking or attenuating Ihh signaling might slow and/or prevent the disease. To test this hypothesis, Control (wild type) and Ctsk-KO mice (9/group) were gavaged daily with the Smoothened inhibitor PF-04449913 (SMOi, 100μg/g body weight) or vehicle control (0.5% methylcellulose), beginning at 5 weeks of age (when early lesions were present) and continuing for the succeeding 4 weeks. Skeletal phenotype was assessed by X-ray, μ-CT, and histology. Remarkably, SMOi treatment significantly reduced the number of exostoses in Ctsk-KO mice (Fig. 4d, S4–7), and dramatically improved their mobility (Supplemental Video clips 1,2), without apparent effects on overall growth rate (Fig. S8). Importantly, SMOi levels in treated mice were adequate to suppress Ihh target gene expression in exostoses (Fig. S7b).
Our findings strongly suggest that MC results from loss of SHP2 specifically in CCPs, a heretofore poorly characterized population within the Perichondrial Groove of Ranvier, which is believed to function as a stem cell niche for joints16 and a reservoir for the germinal layer cells of the growth plate24. Cells within the Groove of Ranvier express high levels of FGFR325, and their removal prevents longitudinal bone growth26. Emerging evidence shows that Groove of Ranvier cells can migrate into articular cartilage16, implicating them in maintaining cartilage homeostasis and possibly in degenerative joint diseases, such as osteoarthritis. Indeed, in lineage tracing studies of normal mice, we noticed YFP+ cells migrating towards articular cartilage (Fig. S9, arrows, and data not shown). Based on our mouse MC model, we propose that SHP2, acting downstream of FGFR3 and upstream of the RAS/ERK pathway, regulates CCP proliferation and chondrogenic differentiation. Consequently, PTPN11 deficiency in these cells promotes excessive proliferation, chondrogenic differentiation, and cartilage tumors.
MC is associated with heterozygous inactivating mutations in PTPN11, yet Ptpn11fl/+;CtskCre mice are normal, whereas Ctsk-KO mice exhibit MC-like features. Although PTPN11 gene dosage effects could differ in mouse and man (and thus 50% reduction in SHP2 level might cause MC in humans but not in mice), we think it is more likely that loss of the remaining PTPN11 allele (e.g., by LOH or silencing) is required to cause cartilage tumors in MC. If so, then unlike its oncogenic role in JMML, other hematologic malignancies and solid tumors1,2, PTPN11 is a tumor suppressor in cartilage. Liver-specific Ptpn11 deletion reportedly results in hepatocellular carcinoma27. However, we have not seen liver tumors in our Ptpn11 conditional knockout mice crossed to the same Cre line (F. H. and B.G.N., manuscript in preparation), nor is PTPN11 mutated in human hepatocellular carcinoma. Moreover, our biochemical and pharmacological analysis, together with previous studies, provide a parsimonious and attractive explanation for the apparently paradoxical pro- and anti-oncogenic effects of PTPN11. In both cases, SHP2 is a critical regulator of ERK. The activating PTPN11 mutations associated with cancer promote proliferation and survival, at least in part via increased ERK activation. Similarly, over-expression or increased activation of normal SHP2 binding proteins such as GAB2, or the presence of pathologic SHP2 binding proteins such as H. pylori CagA28, can hyperactivate ERK and contribute to various malignancies. Conversely, SHP2 deficiency is oncogenic in CCPs because in these cells, ERK normally represses the expression of the growth stimulator IHH (which in turn, stimulates PTHRP production). Future studies should focus on better defining the properties of CCPs, determining whether PTPN11 also acts as a tumor suppressor in other cartilage neoplasms, including chondrosarcoma, and most importantly, on testing the effects of Smoothened inhibition in MC patients. Finally, given our proposed mechanism of MC pathogenesis, our results argue for caution in the long term use of MEK or ERK inhibitors.
Methods
Antibodies and Reagents
The following antibodies were purchased: monoclonal anti-phospho(p)-tyrosine (4G10) was from Millipore; polyclonal antibodies against phospho(p)-Erk1/2, Erk2, p-Akt(Ser473), Akt, Shp2, p-Stat1(Tyr701) and Stat1 were from Cell Signaling; antibodies against Ihh, Col2α1, and Col10α1 were from Santa Cruz Biotechnology and Abcam, respectively; fluorescence-labeled antibodies against CD31, CD44, CD45, CD90, and CD166 were purchased from eBioscience; and antibodies against Stro1 and Jagged1 were purchased from Invitrogen and Epitomics, respectively. Alexa488-labeled goat anti-rabbit IgG and Alexa594-labeled anti-rabbit and anti-mouse IgG were purchased from Invitrogen. FGF18 was purchased from Peprotech. UO126 and PD173074 were from Calbiochem and Selleckbio, respectively. PF-04449913 was kindly provided by Pfizer, Inc. Alcian blue, Alizarin red S, and Oil red O staining solutions were purchased from Poly Scientific.
Cell isolation and culture
To isolate YFP+ cartilage cells (CCPs), epiphyseal cartilage was dissected from 2-week-old Ctsk-Control/YFP and Ctsk-KO/YFP mice, and digested with hyaluronidase (2.5 mg/ml, Sigma) and Trypsin-EDTA (0.25%, Invitrogen) to remove soft tissues, and then with collagenase D (2.5 mg/ml, Roche) for 4–6 hours to release all cartilage cells. After washing in PBS, cells were stained with fluorescence-labeled antibodies (using concentrations recommended by the manufacturers), and analyzed by flow cytometry, or YFP+ cells were purified by FACS and placed in short-term cultures (3–4 days) in murine mesenchymal culture medium (StemCell Technologies) containing 10% FBS.
Parental ATDC5 cells were obtained from Dr. Chanika Phornphutkul (Brown University) and cultured in complete DMEM/F12 medium (1:1) (Invitrogen), as described31. Short hairpin RNAs against mouse Ptpn11 (kd1: 5′-GATTCAGAACACTGGGGACTTCAAGAGAGTCCCCAGTGTTC TGAATC; kd2: 5′-GAGTAACCCTGGAGACTTCTTCAAGAGAGAAGTCTCCAGGGTTA CTC), or a scrambled control for kd1 (5′-TAGTACAAGTCCAAGCGGCTTCAAGAGAGCCGCTGGACTTGTACTA), were introduced into the retroviral vector pSuper(retro)/puro (Oligoengine). Viral supernatants were collected from 293T cells co-transfected with each retroviral vector and Ecopac, and used to infect ATDC5 cells, which were then selected with puromycin32.
Differentiation assays
CCPs (~ 2×104), purified by FACS (for YFP) from 10–14 day old Ctsk-R26LSL-YFP reporter mice, were cultured in differentiation medium for chondrocytes (DMEM with 10% FBS, 0.1μM Dexamethasone, 0.1mM Ascorbic acid, 10mM Glycerol 2-phosphate, TGFβ1 1ng/ml), adipocytes (DMEM with 10% FBS, 1μM Dexamethasone, 0.5mM IBMX, 10ug/ml Insulin), or osteoblasts (DMEM with 10% FBS, 0.1μM Dexamethasone, 0.2mM Ascorbic acid, 10mM Glycerol2-phosphate, 10ng/ml rhMBP2), respectively. After culturing for 2 (adipogenic or chondrogenic differentiation) or 3 weeks (osteogenesis) cells were fixed and stained with Alcian blue, Oil red O or Alizarin red to visualize the formation of cartilage, fate, and bone tissue, respectively.
Quantitative RT-PCR
RNA was extracted from cultured cells or cartilage lesions enriched by laser-capture using the RNeasy kit (Qiagen). cDNA was synthesized using iScript™cDNA Synthesis Kit (Bio-Rad), and qRT-PCR was performed by using the iQ™SYBR®Green qPCR kit. All values were normalized to Gapdh levels, and qRT-PCR data were expressed as fold-increases compared with controls. Primer sequences and PCR conditions are available from W.Y. upon request.
Flow Cytometry and FACS
Epiphyseal cartilage cells were stained with fluorescence-labeled antibodies, as described,33 and analyzed on a BD™ LSR II flow cytometer. YFP+ cells were purified by FACS using a BD Influx™ cell sorter (BD Bioscience, San Diego, CA). Flow cytometric data were analyzed with FlowJo software (TreeStar).
Histology
Ctsk-Control and -KO mice were euthanized at the indicated ages, and femurs, tibiae, and paws were removed and fixed in 4% PFA overnight at 4°C. Postnatal skeletal tissues were decalcified in 0.5M EDTA before embedding. Tissue sections (5μm) were stained with H&E, Alcian blue, or Safranin O. Immunofluorescence staining was carried out using secondary antibodies conjugated to the indicated fluorophores at concentrations recommended by their manufacturers. Immunohistochemistry was performed using fluorescence- or peroxidase-coupled anti-rabbit, mouse, or -goat secondary antibodies, as per the manufacturer’s instructions, with DAB serving as the substrate. X-gal staining was performed as described12.
Drug Treatment
Two trials were performed using the Smoothened inhibitor PF-04449913. In a pilot study, groups (5 mice/each) of KO mice were treated with SMOi (100μg/g body weight) or vehicle control (0.5% methylcellulose), beginning at 5 weeks of age (at which time early lesions were present) and continuing for the succeeding 4 weeks. Mice were randomized by alternate assignment to control (vehicle) or drug treatment arms. The pilot experiment showed a significant difference in number of exostoses (assessed radiographically) in the SMOi group, and led to a second study (again involving 5 mice each) to confirm these findings and also assess additional parameters (μCT, histology, gene expression). Two mice (one each from control and experimental groups, respectively) died for unknown reasons during the second trial, and were excluded from the analysis because they were removed from cages and could not be recovered. All surviving mice from both studies were included in the analyses shown in the text.
Microcomputed Tomography (μ-CT) and X-Ray Analysis
X-ray images of the entire skeleton, knees, metatarsals and phalanges were obtained immediately after euthanasia by using a Faxitron X-ray system (Wheeling, Illinois). After fixation in 4% PFA, μ-CT images of skeletal tissues were scanned with a desktop microcomputer graphic imaging system (μ-CT40, Scanco Medical AG, CH). The number of exostoses was measured from these radiographic images, as indicated in the Figure legends. For these studies, mice were assigned a code number by the animal technician, and blinded quantification was carried out by W.Y.
Immunoblotting
Cells were lysed in NP-40 buffer (0.5% NP40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris [pH 7.4]), supplemented with a protease inhibitor cocktail (1 mM PMSF, 1 mM NaF, 1 mM sodium orthovanadate, 10 mg/ml aprotinin, 0.5 mg/ml antipain, and 0.5 mg/ml pepstatin), as described10. For immunoblotting, cell lysates (10–50 μg) were resolved by SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibodies for 2 hr or overnight at 4°C (according to the manufacturer’s instructions), followed by HRP-conjugated secondary antibodies. Detection was by enhanced chemiluminescence (Amersham). Signals were quantified using NIH ImageJ.
Statistical Analysis
Differences between groups were evaluated by Student’s t test. A p value of <0.05 was considered significant. For all of these experiments, between groups variances were similar and data were symmetrically distributed. All analyses were performed by using Excel (Microsoft, Redmond, WA) and Prism 3.0 (GraphPad, San Diego, CA).
Acknowledgments
We thank Dr. Shigeaki Kato (University of Tokyo) for Ctsk-Cre mice, Dr. April Craft (Princess Margaret Cancer Center) for review of the manuscript, Ms. Xiaohong Wang and Mr. Paul Monfils for help with histology, and Dr. Jay Cao (USDA) for helping μ-CT analysis. This publication was made possible by NIH and the National Institute for General Medicine Sciences (NIGMS) Grant #8P20GM103468. This work was also funded by NIH R21AR57156 (to W.Y) and R37CA49152 (to B.G.N.), the Rhode Island Hospital Orthopaedic Foundation and a grant from the Pediatric Orthopaedic Society of North America and the Orthopaedic Research and Education Foundation (to W.Y.). B.G.N. is a Canada Research Chair, Tier 1, and also is supported in part by the Ontario Ministry of Health and Long Term Care and the Princess Margaret Cancer Foundation.
Footnotes
Competing interests statement
W.Y. and B.G. N. have filed a provisional patent application on the use of Smoothened inhibitors for the treatment of metachondromatosis (Title: Hedgehog Pathway Inhibition for Cartilage Tumor and Metachondromatosis Treatment; UPA#61/614,449).
Author Contributions W.Y. and B.G.N. conceived the project. J.W., D.M., H.L., and W.Y. carried out most of the experiments. M.D. and W.Y. conducted FACS sorting and analysis. H.L. performed SMOi animal treatment experiment. J.W. performed gene expression and western blot analysis. M.D. and J.W carried out bone marrow transplantation experiments with the advice of P.J.Q.. M.D., H.L and W.Y. performed CPC multi-lineage differentiation assays. Q.W. and R.T. performed histological staining and data interpretation. Q.C. and M.G.E. provided technical and intellectual support. W.Y. and B.G.N. analyzed the data and wrote the manuscript with the help of all authors.